Psychiatric Times January 20, 2025
Michael Asbach, DMSc, PA-C, Psych-CAQ

Key Takeaways

  • COVID-19 has significantly impacted psychiatric research and drug development, emphasizing the high costs and challenges of clinical trials.
  • AI and technology hold transformative potential for advancing psychiatric research methodologies, according to Michael Asbach.
  • The pandemic may serve as a catalyst for innovation and improvement in psychiatric research, fostering long-term advancements.
  • Asbach’s clinic is involved in nearly 100 clinical trials, with some still recruiting participants from the COVID era.

Let’s explore COVID-19’s impact on psychiatric research…

CONFERENCE REPORTER

At the Real Psychiatry conference, Michael Asbach, DMSc, PA-C, Psych-CAQ, shared how he feels COVID-19 impacted psychiatric research and drug development.

“It really does have an incredible impact on drug development, especially when you think...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Healthcare System, Mental Health, Pharma, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
Improving Access to Behavioral Health Crisis Support Services
Out of Her Mind: How We Are Failing Women’s Mental Health and What Must Change
Investing in adolescent mental health delivers long-term economic and social benefits
Face-to-face exercise programs improve mental health in heart disease patients
Rethinking mental health research through AI-driven simulations

Share This Article